GlassScriptPhysician profile
Kevin B Collins
NPI 1174611511
$2,800.02
in general payments reported to CMS, 2019-2025
40 companies · $574 in 2025
The $574 reported for 2025 was more than what 77% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $43.15 · 2021: $60.49 · 2022: $314 · 2023: $748 · 2024: $944 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,266.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $292.41 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $272.19 | 2022-2025 | |
| Exelixis INC. | $214.89 | 2019-2025 | Cabometyx |
| Abbvie INC. | $210.04 | 2023-2025 | Venclexta |
| Astrazeneca Pharmaceuticals LP | $178.72 | 2022-2024 | Enhertu, Lynparza, Imfinzi |
| Janssen Biotech, INC. | $168.16 | 2019-2024 | Imbruvica, Rybrevant, Darzalex |
| Daiichi Sankyo INC. | $161.36 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Lilly USA, LLC | $139.42 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $118.02 | 2022-2025 | |
| Genzyme Corporation | $116.47 | 2019-2025 | |
| Beigene USA, INC. | $101.71 | 2022-2024 | Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.33 | 2023-2025 | Gilotrif |
| Reflexion Medical, INC. | $63.37 | 2024 | Reflexion Medical Radiotherapy System |
| Aveo Pharmaceuticals, INC. | $62.44 | 2023-2025 | Fotivda |
| Amgen INC. | $48.70 | 2022-2023 | Lumakras |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.